Edition:
India

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

82.11USD
12:18am IST
Change (% chg)

$0.13 (+0.16%)
Prev Close
$81.98
Open
$81.31
Day's High
$83.67
Day's Low
$79.66
Volume
1,197,357
Avg. Vol
1,436,387
52-wk High
$88.76
52-wk Low
$65.44

Latest Key Developments (Source: Significant Developments)

Abbott Reports Third-Quarter 2019 Results
Wednesday, 16 Oct 2019 

Oct 16 (Reuters) - Abbott Laboratories ::ABBOTT REPORTS THIRD-QUARTER 2019 RESULTS.Q3 ADJUSTED EARNINGS PER SHARE $0.84 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.Q3 GAAP EARNINGS PER SHARE $0.53 FROM CONTINUING OPERATIONS.Q3 EARNINGS PER SHARE ESTIMATE $0.84 -- REFINITIV IBES DATA.SEES Q4 ADJUSTED EARNINGS PER SHARE $0.94 TO $0.96 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $3.23 TO $3.25 FROM CONTINUING OPERATIONS.SEES Q4 2019 GAAP EARNINGS PER SHARE $0.59 TO $0.61 FROM CONTINUING OPERATIONS.SEES FY 2019 GAAP EARNINGS PER SHARE $2.06 TO $2.08 FROM CONTINUING OPERATIONS.THIRD-QUARTER WORLDWIDE SALES OF $8.1 BILLION INCREASED 5.5 PERCENT ON A REPORTED BASIS.NARROWING GUIDANCE FOR 2019 GAAP EARNINGS PER SHARE FROM CONTINUING OPERATIONS.FORECASTS NET SPECIFIED ITEMS FOR FY 2019 OF $1.17 PER SHARE.RIGHT ON TRACK TO ACHIEVE ONGOING EPS & ORGANIC SALES GROWTH AT UPPER-END OF OUR INITIAL GUIDANCE RANGES FOR YEAR.FY2019 EARNINGS PER SHARE VIEW $3.24 -- REFINITIV IBES DATA.QTRLY TOTAL NUTRITION SALES $1.87 BILLION, UP 2% ON REPORTED BASIS.QTRLY TOTAL NUTRITION PEDIATRIC SALES $1,044 MILLION, UP 0.5% ON REPORTED BASIS.FREESTYLE LIBRE ACHIEVED WORLDWIDE SALES OF $496 MILLION IN QUARTER, UP 63.1% ON REPORTED BASIS.QTRLY TOTAL DIAGNOSTICS SALES $1.91 BILLION, UP 4.7% ON REPORTED BASIS.  Full Article

Abbott Laboratories - On October 11, Board Authorized Repurchase Of Up To $3 Billion Of Abbott Shares
Tuesday, 15 Oct 2019 

Oct 15 (Reuters) - Abbott Laboratories ::ABBOTT LABORATORIES - ON OCTOBER 11, BOARD AUTHORIZED REPURCHASE OF UP TO $3 BILLION OF ABBOTT SHARES.ABBOTT SAYS NEW AUTHORIZATION IS IN ADDITION TO $795 MILLION UNUSED PORTION OF PREVIOUS SHARE REPURCHASE PROGRAM - SEC FILING.  Full Article

Omada Health Says Co, Abbott To Integrate Abbott's Freestyle Libre System With Co's Digital Care Program
Monday, 14 Oct 2019 

Oct 14 (Reuters) - Abbott Laboratories ::OMADA HEALTH SAYS CO, ABBOTT TO INTEGRATE ABBOTT'S FREESTYLE LIBRE SYSTEM WITH CO'S DIGITAL CARE PROGRAM.  Full Article

Abbott Laboratories Says Late-Breaking Data Shows Mitraclip Increases Life Expectancy
Sunday, 29 Sep 2019 

Sept 29 (Reuters) - Abbott Laboratories ::LATE-BREAKING DATA SHOWS ABBOTT'S MITRACLIP™ IS COST EFFECTIVE, INCREASES LIFE EXPECTANCY AND IMPROVES QUALITY OF LIFE.  Full Article

Abbott CEO Says FreeStyle Libre Can Achieve $5 Bln In Sales "In A Reasonable Time"
Wednesday, 17 Jul 2019 

July 17 (Reuters) - Abbott Laboratories ::ABBOTT LABORATORIES SAYS HAS RESEARCH AND DEVELOPMENT PROGRAMS UNDERWAY NOT ONLY FOR ENHANCEMENT AND EXPANSION OF FREESTYLE LIBRE, BUT ALSO IN CATEGORIES BEYOND DIABETES.ABBOTT LABORATORIES CEO SAYS FREESTYLE LIBRE CAN ACHIEVE $5 BILLION IN SALES "IN A REASONABLE TIME".  Full Article

Abbott Receives U.S. Approval Of Next-Generation Mitraclip
Monday, 15 Jul 2019 

July 15 (Reuters) - Abbott Laboratories ::ABBOTT RECEIVES U.S. APPROVAL OF NEXT-GENERATION MITRACLIP®, BRINGING NEW ENHANCEMENTS TO ABBOTT'S LEADING MITRACLIP PLATFORM.ABBOTT LABORATORIES - CO HAS RECEIVED U.S. FDA APPROVAL FOR MOST ADVANCED MITRACLIP HEART VALVE REPAIR DEVICE TO TREAT MITRAL REGURGITATION.  Full Article

Enzo Biochem Says CO Considering All Available Options For Challenging Federal Circuit Panel's Decision
Saturday, 22 Jun 2019 

June 21 (Reuters) - Abbott Laboratories ::ENZO BIOCHEM - U.S. COURT OF APPEALS ISSUED OPINION AFFIRMING LOWER COURT JUDGMENTS OF PATENT INVALIDITY FOR U.S. PATENT NOS. 6,992,180 & 8,097,405.ENZO BIOCHEM INC - COMPANY IS CONSIDERING ALL AVAILABLE OPTIONS FOR CHALLENGING FEDERAL CIRCUIT PANEL'S DECISION.  Full Article

New Data for Abbott's HeartMate 3 Highlights Unparalleled Performance of Industry's Leading Heart Pump
Sunday, 17 Mar 2019 

March 17 (Reuters) - Abbott Laboratories ::MOMENTUM 3 MET ITS PRIMARY ENDPOINT OF EVENT FREE SURVIVAL WHILE SHOWCASING IMPROVED RATES OF OVERALL SURVIVAL.  Full Article

Roger Bird, Svp Of Abbott Laboratories Reports Open Market Sale Of 9,188 Shares Of Co Priced Between $79.061-$79.0714- SEC Filing
Friday, 15 Mar 2019 

March 14 (Reuters) - Abbott Laboratories ::ROGER BIRD, SVP OF ABBOTT LABORATORIES REPORTED OPEN MARKET SALE OF 9,188 SHARES OF CO PRICED BETWEEN $79.061-$79.0714 ON MARCH 13 - SEC FILING.  Full Article

FDA Approves New Indication For Abbott's Valve Repair Device
Thursday, 14 Mar 2019 

March 14 (Reuters) - FDA::FDA APPROVES NEW INDICATION FOR VALVE REPAIR DEVICE TO TREAT CERTAIN HEART FAILURE PATIENTS WITH MITRAL REGURGITATION.FDA SAYS MITRACLIP CLIP DELIVERY SYSTEM IS MANUFACTURED BY ABBOTT VASCULAR INC..  Full Article

Purdue OxyContin settlement would rank among largest in pharma history

OxyContin maker Purdue Pharma LP has reached a tentative multibillion-dollar agreement with some plaintiffs aimed at settling thousands of lawsuits over its alleged role in the U.S. opioid crisis, Reuters reported on Wednesday, citing people familiar with the matter.